Dr. Julia Rossié
Biography
Dr. Julia Rossié is a senior associate in the Transactional Practice Group in New York who advises domestic and international clients on a wide range of corporate matters, focusing on mergers and acquisitions (M&A), private equity, growth capital, and venture capital transactions. She has a particular focus on the healthcare and life sciences industry.
Practice Focus
Julia advises her clients, including national and international financial investors, pharmaceutical or biotech companies and family offices, on a wide range of corporate and intellectual property focused transactions. Julia also has a deep understanding of the legal, intellectual property and regulatory issues involved in these transactions.
Representative Legal Matters
- Astellas in its exclusive option and license agreement with AviadoBio for an investigational gene therapy targeting frontotemporal dementia, including a USD 20 million equity investment and up to USD 30 million in option exercise payments, plus the potential for USD 2.18 billion in license fees and milestone payments plus royalties if Astellas exercises its option.
- Evonik Industries AG on its virtually held annual general meeting.
- Seamless Therapeutics on USD 12.5 million Financing and In-Licensing from TU Dresden.
- Ariceum Therapeutics on a Serie A Financing - co-led by EQT Life Sciences (formerly LSP) and HealthCap - and on an Asset Acquisition from Ipsen Pharma.
- CatalYm GmbH, an innovative biotech company developing novel cancer immunotherapies, on the closing of its EUR 50 million Series B equity financing.
- AURELIUS Equity Opportunities SE & Co. KGaA on the sale of its subsidiary GHOTEL hotel & living to the Cologne-based Art-Invest Real Estate Group.
- German biotech company MODAG on the in-licensing of an innovative substance portfolio (SERY 433) from Max Planck Innovation GmbH to combat neurodegenerative diseases and on the closing of a EUR 12 million Series A financing round, led by the Massa Investment AG, Switzerland.
- Hitachi Chemical Company, Ltd., a leading manufacturer of functional materials and advanced components with a strong portfolio in the life sciences industry, on the takeover of German apceth Biopharma, a contract development and manufacturing organization for complex cell-based regenerative gene therapy products.
Admissions
- Germany (2018)
Education
- Higher Regional Court of Hamburg (Assessor Exam) (2018)
- University of Munich (Legal Clerk Exam) (2013)
- Qingdao University (2011)
- University of Salamanca (2011)
Languages
- English
- German
- Spanish
Previous Offices
Munich
Baker & McKenzie LLP is a Limited Liability Partnership organized under the laws of the State of Illinois (USA) and is a member of Baker & McKenzie International, a Verein organized under the laws of Switzerland.